ClinicalTrials.gg
CompletedNCT00490945Updated Aug 26, 2014Results posted

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

A Phase 2 interventional study of VEC-162 in Circadian Rhythm Sleep Disorders, sponsored by Vanda Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-26.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Enrollment
30th of 54
45 · median 50
Started
2004
with 1 other
Phase 2
5 of 69
1 open now
Registered
9th of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 30th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2004, is one of 5 in phase 2, and was the 9th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.

03

Conditions studied

  • Circadian Rhythm Sleep Disorders
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No medical, psychiatric, or sleep disorders
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of night shift work
  • Evidence of any sleep disorder
  • Psychiatric or neurological disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
45 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Circadian Phase Shift

    Exposure response to VEC-162 on induction of circadian phase shift as measured by Dim Light Melatonin Onset (DLMO) was defined as the time change between Night 3 and Night 4 when melatonin production reached 25% of the maximum melatonin concentration. Samples below LOQ of the melatonin assay were assigned 5 pg/ml.

    Time frame: Night 3 and Night 4

  2. Mean Sleep Efficiency

    Exposure response was measured by comparing the change in sleep efficiencies of VEC-162 and placebo treated subjects upon a sleep schedule phase advance. Sleep efficiency (total time asleep divided by the time allowed as an opportunity for sleep in a period multiplied by 100%, where time allowed for sleep was 8 hours or 480 minutes) was measured objectively by overnight polysomnographic recordings. Sleep efficiency was also compared in parts of the night by dividing the full night into thirds.

    Time frame: Night 4 and Night 2

Secondary outcomes

  1. Wake After Sleep Onset (WASO), and Latency to Persistent Sleep (LPS)

    Wake After Sleep Onset is defined as the total time that is scored as awake in a PSG occurring between sleep onset and lights-on prompt. Latency to Persistent Sleep is defined as the number of epochs (one 30-second interval of the sleep episode) from the beginning of the recording (lights-out) to the start of persistent sleep (first 20 consecutive non-wake state) divided by 2.

    Time frame: Night 2 and Night 4

  2. VEC-162 AUC

    Time frame: Night 4

  3. VEC-162 Cmax

    Time frame: Night 4

  4. VEC-162 Tmax

    Time frame: Night 4

07

Results

Posted Aug 26, 2014

Participant flow

Participant flow — Overall Study
MilestonePlacebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
Started89877
Completed88877
Not completed01000
Withdrew: Adverse event01000

Outcome measures

PrimaryCircadian Phase Shift

Exposure response to VEC-162 on induction of circadian phase shift as measured by Dim Light Melatonin Onset (DLMO) was defined as the time change between Night 3 and Night 4 when melatonin production reached 25% of the maximum melatonin concentration. Samples below LOQ of the melatonin assay were assigned 5 pg/ml.

Time frame:
Night 3 and Night 4
Reported as:
Mean · Hours
Circadian Phase Shift
HoursPlacebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
Circadian Phase Shift-0.48 ± 0.840.18 ± 2.48-1.14 ± 0.46-0.50 ± 0.32-2.74 ± 1.95
PrimaryMean Sleep Efficiency

Exposure response was measured by comparing the change in sleep efficiencies of VEC-162 and placebo treated subjects upon a sleep schedule phase advance. Sleep efficiency (total time asleep divided by the time allowed as an opportunity for sleep in a period multiplied by 100%, where time allowed for sleep was 8 hours or 480 minutes) was measured objectively by overnight polysomnographic recordings. Sleep efficiency was also compared in parts of the night by dividing the full night into thirds.

Time frame:
Night 4 and Night 2
Reported as:
Mean · % points
Mean Sleep Efficiency
% pointsPlacebo*10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
Full Night (% points)-20.27 ± 18.72-7.77 ± 14.98-6.68 ± 12.69-5.87 ± 9.89-2.02 ± 4.94
1st Third of the Night (% points)-12.30 ± 14.51-0.47 ± 12.39-7.81 ± 14.520.95 ± 7.79-5.63 ± 17.71
2nd Third of the Night (% points)-34.92 ± 38.23-12.64 ± 13.83-5.11 ± 12.78-2.10 ± 4.14-2.30 ± 5.72
3rd Third of the NIght (% points)-8.06 ± 29.69-10.51 ± 35.17-7.09 ± 26.24-16.48 ± 26.251.80 ± 14.15
SecondaryWake After Sleep Onset (WASO), and Latency to Persistent Sleep (LPS)

Wake After Sleep Onset is defined as the total time that is scored as awake in a PSG occurring between sleep onset and lights-on prompt. Latency to Persistent Sleep is defined as the number of epochs (one 30-second interval of the sleep episode) from the beginning of the recording (lights-out) to the start of persistent sleep (first 20 consecutive non-wake state) divided by 2.

Time frame:
Night 2 and Night 4
Reported as:
Mean · minutes
Wake After Sleep Onset (WASO), and Latency to Persistent Sleep (LPS)
minutesPlacebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
Latency to Persistent Sleep15.13 ± 21.25-8.25 ± 16.345.00 ± 11.89-3.71 ± 10.97-4.17 ± 6.93
WASO*77.00 ± 91.0140.56 ± 67.5331.19 ± 53.8031.21 ± 52.698.50 ± 20.39
SecondaryVEC-162 AUC
Time frame:
Night 4
Reported as:
Mean · ng*hr/mL
VEC-162 AUC
ng*hr/mL10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
VEC-162 AUC171.73 ± 118.51482.00 ± 329.48614.34 ± 488.081916.06 ± 601.35
SecondaryVEC-162 Cmax
Time frame:
Night 4
Reported as:
Mean · ng/mL
VEC-162 Cmax
ng/mL10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
VEC-162 Cmax59.10 ± 39.22139.94 ± 116.10166.01 ± 164.94417.80 ± 187.19
SecondaryVEC-162 Tmax
Time frame:
Night 4
Reported as:
Mean · hour
VEC-162 Tmax
hour10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
VEC-162 Tmax1.90 ± 1.782.04 ± 0.902.42 ± 0.593.03 ± 1.50

Adverse events

Collected over 1st dose to 30 days following last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/8 (0%)8/8 (100%)
10 mg VEC-162—0/9 (0%)8/9 (88.9%)
20 mg VEC-162—0/8 (0%)7/8 (87.5%)
50 mg VEC-162—0/7 (0%)7/7 (100%)
100 mg VEC-162—0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPlacebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162
SomnolenceNervous system disorders4/83/92/85/72/7
Haematocrit DecreasedInvestigations3/84/93/84/74/7
Haemoglobin DecreasedInvestigations2/83/90/82/73/7
Application Site IrritationGeneral disorders3/81/92/80/70/7
Injection Site PainGeneral disorders1/81/91/82/71/7
Application Site PainGeneral disorders1/80/90/82/71/7
HeadacheNervous system disorders2/81/91/81/72/7
NervousnessPsychiatric disorders0/80/90/82/70/7
NauseaGastrointestinal disorders2/81/90/81/70/7
Abdominal Pain UpperGastrointestinal disorders0/80/92/81/70/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162Total
Mean27.5 ± 6.731.8 ± 7.432.5 ± 9.627.4 ± 6.230.4 ± 9.530.0 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo10 mg VEC-16220 mg VEC-16250 mg VEC-162100 mg VEC-162Total
Female5344420
Male3643319
08

Study locations

2 sites
  • Vanda Investigational Site
    Boston, Massachusetts, United States
  • Vanda Investigational Site
    Detroit, Michigan, United States
09

References and documents

Publications

  • Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Erratum In: Lancet. 2009 Apr 11;373(9671):1252. PubMed 19054552 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Mar 2005 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2007
First posted
Jun 25, 2007
Start
Jul 2004
Primary completionActual
Mar 2005
CompletionActual
Mar 2005
Results first posted
Aug 26, 2014
Last update
Aug 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00490945
First posted
Jun 25, 2007
Start date
Jul 2004
Primary completion
Mar 2005
Completion
Mar 2005
Results posted
Aug 26, 2014
Last update
Aug 26, 2014

Study contacts

Marlene Dressman, PhD
study director · Vanda Pharmaceuticals Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion